Disease Information & Support


The Word:


Generic name Denileukin diftitox
Pronunciation DEN-i-loo-kin DIF-ti-toks
Brand name(s), other common name(s) Ontak®
Drug type  DNA-damaging agent
How the drug is given Intravenously (IV)

Denileukin diftitox is FDA approved to treat people who have persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.

Side effects needing medical attention: Back pain or lower back pain or side pain accompanied by fever or chills; chest pain; dizziness or faintness; difficulty swallowing; fast or irregular heartbeat; fever or chills; infection; rash; shortness of breath; swelling of face, feet or lower legs; warmth and flushing of skin; severe abdominal pain; black, tarry stools; cloudy urine; blood in urine or stool; cough or hoarseness accompanied by fever or chills; severe headache; loss of coordination; painful or difficult urination accompanied by fever or chills; pain in groin or leg; pinhead-sized red spots on skin; slurring of speech; sudden vision changes; swelling or pain at injection site; unusual bleeding or bruising; weakness of arms or legs; difficulty swallowing; loss of strength or energy; nausea; pain in joints and muscles; unusual tiredness or weakness; vomiting; cough; diarrhea; sore throat; trouble sleeping.


For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.

last updated on Monday, October 15, 2012